US equities |
MU $1,022.75 ▼-1.26% TSLA $382.58 ▲+2.02% SPCX $163.13 ▲+1.59% NVDA $230.01 ▼-0.20% AAPL $334.18 ▼-1.83% SNDK $1,599.09 ▼-0.64% AMD $612.00 ▼-1.40% AMZN $261.14 ▲+2.79%
FinancialContent

Equillium, Inc. - Common Stock (NQ:EQ)

1.420 -0.020 (-1.39%)
Delayed Quote Updated: 11:40 AM EDT, Oct 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Equillium, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Equillium, Inc.
Via Business Wire
News headline image
Equillium to Participate in the Cantor Global Healthcare Conference 2025
From Equillium, Inc.
Via Business Wire
News headline image
Wall Street Eyes: EQ, PRSO, WLGS, ENTO, GIBO Stocks Lead Sub-$1 Surge
Via AB Newswire
Topics Artificial Intelligence
News headline image
Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic
From Equillium, Inc.
Via Business Wire
News headline image
Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve Strategy
From Equillium, Inc.
Via Business Wire
News headline image
Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists
From Equillium, Inc.
Via Business Wire
News headline image
Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504
From Equillium, Inc.
Via Business Wire
News headline image
Equillium Announces Feedback from the U.S. Food and Drug Administration
From Equillium, Inc.
Via Business Wire
News headline image
Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights
From Equillium, Inc.
Via Business Wire
News headline image
Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease
From Equillium, Inc.
Via Business Wire
News headline image
Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis
From Equillium, Inc.
Via Business Wire
News headline image
Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates
From Equillium, Inc.
Via Business Wire
News headline image
Equillium to Present at the Stifel Healthcare Conference
From Equillium, Inc.
Via Business Wire
News headline image
Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer
From Equillium Inc.
Via Business Wire
News headline image
Equillium Maintains Rights to Itolizumab Following Ono Partnership
From Equillium Inc.
Via Business Wire
News headline image
Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer
From Equillium, Inc.
Via Business Wire
News headline image
Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit
From Equillium, Inc.
Via Business Wire
News headline image
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Equillium, Inc.
Via Business Wire
News headline image
Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference
From Equillium, Inc.
Via Business Wire
News headline image
Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights
From Equillium Inc.
Via Business Wire
News headline image
Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
From Equillium, Inc.
Via Business Wire
News headline image
Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance
From Equillium, Inc.
Via Business Wire
News headline image
Equillium to Participate in Upcoming Investor Conferences
From Equillium, Inc.
Via Business Wire
News headline image
Equillium to be included in the Russell Microcap® Index
From Equillium, Inc.
Via Business Wire
News headline image
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Equillium, Inc.
Via Business Wire
News headline image
Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata
From Equillium Inc.
Via Business Wire
News headline image
Equillium to Present at the Jefferies Global Healthcare Conference
From Equillium, Inc.
Via Business Wire
News headline image
Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
From Equillium, Inc.
Via Business Wire
News headline image
Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights
From Equillium Inc.
Via Business Wire
News headline image
Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists
From Equillium, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >